{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:23:47Z","timestamp":1790357027849,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV)\u2010viremic organs are underutilized, and there is limited real\u2010world experience on the transplantation of HCV\u2010viremic solid organs into recipients who are HCV negative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>\n                      Patients listed or being evaluated for solid organ transplant after January 26, 2018, were educated and consented by protocol on the transplantation of HCV\u2010viremic organs. All recipients were HCV nucleic acid test and anti\u2010HCV antibody negative at the time of transplant and received an HCV\u2010viremic organ. The primary outcome was sustained virological response (SVR) at 12 weeks after completion of direct\u2010acting antiviral (DAA) therapy (SVR\n                      <jats:sub>12<\/jats:sub>\n                      ). Seventy\u2010seven patients who were HCV negative underwent solid organ transplantation from a donor who was HCV viremic. No patients had evidence of advanced hepatic fibrosis. Treatment regimen and duration were at the discretion of the hepatologist. Sixty\u2010four patients underwent kidney transplant (KT), and 58 KT recipients had either started or completed DAA therapy. Forty\u2010one achieved SVR\n                      <jats:sub>12<\/jats:sub>\n                      , 10 had undetectable viral loads but are not eligible for SVR\n                      <jats:sub>12<\/jats:sub>\n                      , and 7 remain on treatment. One KT recipient was a nonresponder because of nonstructural protein 5A resistance. Four patients underwent liver transplant and 2 underwent liver\u2010kidney transplant. Three patients achieved SVR\n                      <jats:sub>12<\/jats:sub>\n                      , 1 has completed DAA therapy, and 2 remain on treatment. Six patients underwent heart transplant and 1 underwent heart\u2010kidney transplant. Six patients achieved SVR\n                      <jats:sub>12<\/jats:sub>\n                      and 1 patient remains on treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Limited data exist on the transplantation of HCV\u2010viremic organs into recipients who are HCV negative. Our study is the largest to describe a real\u2010world experience of the transplantation of HCV\u2010viremic organs into recipients who are aviremic. In carefully selected patients, the use of HCV\u2010viremic grafts in the DAA era appears to be efficacious and well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.31011","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T02:28:25Z","timestamp":1572316105000},"page":"32-41","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":109,"title":["Hepatitis C Virus NAT\u2010Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus\u2013Negative Recipients: A Real\u2010World Experience"],"prefix":"10.1097","volume":"72","author":[{"given":"Nikhil","family":"Kapila","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Cleveland Clinic Florida,Weston,FL"},{"name":"Department of Gastroenterology and Hepatology,Duke University,Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.V. Narayanan","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic,Cleveland,OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawtar","family":"Al\u2010Khalloufi","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Vanatta","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Murgas","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Reino","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ebaid","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerja","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Rhazouani","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Navas","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Sheffield","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad Ur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Castillo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,Cleveland Clinic,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina C.","family":"Lindenmeyer","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic,Cleveland,OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic,Cleveland,OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Quintini","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic,Cleveland,OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xaralambos B.","family":"Zervos","sequence":"additional","affiliation":[{"name":"Department of Transplant,Cleveland Clinic Florida,Weston,FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"hep31011-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","year":"1999","journal-title":"N Engl J Med"},{"key":"hep31011-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1681\/ASN.V123589","article-title":"Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait\u2010listed transplant candidates","volume":"12","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"hep31011-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamasurg.2014.2038","article-title":"Survival benefit of solid\u2010organ transplant in the United States","volume":"150","year":"2015","journal-title":"JAMA Surg"},{"key":"hep31011-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1111\/ajt.13971","article-title":"Improving organ utilization to help overcome the tragedies of the opioid epidemic","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.29572","article-title":"The rise of the opioid epidemic and hepatitis C\u2010positive organs: A new era in liver transplantation","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep31011-bib-0007-20241017","first-page":"1586","article-title":"Interferon\u2010based combination anti\u2010viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"5","year":"2006","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0008-20241017","article-title":"Interferon\u2010based anti\u2010viral therapy for hepatitis C virus infection after renal transplantation: an updated meta\u2010analysis","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"hep31011-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C\u2010positive kidneys for hepatitis C\u2010positive recipients","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2014.04.037","article-title":"A US multicenter study of hepatitis C treatment of liver transplant recipients with protease\u2010inhibitor triple therapy","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"hep31011-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patient with hepatitis C virus infection","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep31011-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/jvh.13042","article-title":"Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin","volume":"26","year":"2019","journal-title":"J Viral Hepat"},{"key":"hep31011-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/tri.12954","article-title":"Transplantation of kidneys from hepatitis C\u2010positive donors into hepatitis C virus\u2010infected recipients followed by early initiation of direct acting antiviral therapy: a single\u2010center retrospective study","volume":"30","year":"2017","journal-title":"Transpl Int"},{"key":"hep31011-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV\u2010infected kidneys into uninfected recipients","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"hep31011-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve\u2010month outcomes after transplant of Hepatitis C\u2010infected kidneys into uninfected recipients: A single\u2010group trial","volume":"169","year":"2018","journal-title":"Ann Intern Med"},{"key":"hep31011-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct\u2010acting antiviral prophylaxis in kidney transplantation from hepatitis C virus\u2010infected donors to noninfected recipients: An open\u2010label nonrandomized trial","volume":"168","year":"2018","journal-title":"Ann Intern Med"},{"key":"hep31011-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.healun.2018.01.1293","article-title":"Early outcomes using hepatitis C\u2010positive donor for cardiac transplantation in the era of effective direct\u2010acting anti\u2010viral therapies","volume":"37","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"hep31011-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1111\/ajt.15311","article-title":"Transplanting hepatitis C virus\u2013infected hearts into uninfected recipients: A single\u2010arm trial","volume":"19","year":"2019","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and Lung Transplants from HCV\u2010Infected Donors to Uninfected Recipients","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"hep31011-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.15162","article-title":"Liver transplantation for hepatitis C virus (HCV) non\u2010viremic recipients with HCV viremic donors","volume":"19","year":"2019","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0022-20241017","article-title":"Successful treatment of donor\u2010derived hepatitis C infection in a lung transplant recipient","volume":"19","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"hep31011-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting Hepatitis C\u2010Positive Kidneys","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep31011-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon\u2010based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","year":"2006","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","year":"2008","journal-title":"J Hepatol"},{"key":"hep31011-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/j.1600-6143.2006.01374.x","article-title":"Acute renal allograft rejection following pegylated IFN\u2010alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report","volume":"6","year":"2006","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00007890-199801150-00026","article-title":"A 20\u2010year case study of a kidney transplant recipient with chronic active hepatitis C: a clinical course and successful treatment for late cute rejection induced by interferon therapy","volume":"65","year":"1998","journal-title":"Transplantation"},{"key":"hep31011-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","year":"2010","journal-title":"Transplantation"},{"key":"hep31011-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: a meta\u2010analysis of observational studies","volume":"5","year":"2005","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00535-017-1310-9","article-title":"Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience","volume":"52","year":"2017","journal-title":"J Gastroenterol"},{"key":"hep31011-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep31011-bib-0032-20241017","first-page":"140","article-title":"Management of hepatitis C post\u2010liver transplantation: a comprehensive review","volume":"3","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"hep31011-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir\u2010sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: A randomized trial","volume":"166","year":"2017","journal-title":"Ann Intern Med"},{"key":"hep31011-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and Safety of Sofosbuvir\u2010Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"hep31011-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/hep.30540","article-title":"Increasing utilization and excellent initial outcomes following liver transplant of HCV\u2010viremic donors into HCV\u2010negative recipients","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep31011-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post\u2013liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","year":"2010","journal-title":"Liver Transpl"},{"key":"hep31011-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/jvh.12712","article-title":"Long\u2010term outcomes of direct acting antivirals in post\u2010transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis","volume":"24","year":"2017","journal-title":"J Viral Hepat"},{"key":"hep31011-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.cgh.2015.05.030","article-title":"Efficacy of sofosbuvir and dacltasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31011-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/lt.24985","article-title":"Hepatitis C viremic donors for hepatitis C nonviremic liver transplant recipients: Ready for prime time?","volume":"24","year":"2018","journal-title":"Liver Transpl"},{"key":"hep31011-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ajg.2017.87","article-title":"Medicaid reimbursement for oral direct antiviral agents for the treatment of chronic hepatitis C","volume":"112","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"hep31011-bib-0041-20241017","article-title":"Drug authorization for sofosbuvir\/ledipasvir (Harvoni) for chronic HCV infection in a real\u2010world cohort: a new barrier in the HCV care cascade","volume":"10","year":"2015","journal-title":"PLoS ONE"},{"key":"hep31011-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/cid\/civ677","article-title":"Access to costly new hepatitis C drugs: medicine, money, and advocacy","volume":"61","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31011","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:21:02Z","timestamp":1729192862000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31011","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"2019-05-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}